Diagnosis of myositis-associated interstitial lung disease: Utility of the myositis autoantibody line immunoassay. (October 2021)

• Record Type: Journal Article
• Authors: Jee, Adelle S.; Parker, Matthew J.S.; Bleasel, Jane F.; Troy, Lauren K.; Lau, Edmund M.; Jo, Helen E.; Teoh, Alan K.Y.; Webster, Susanne; Adelstein, Stephen; Corte, Tamera J.
• Is Part Of: Respiratory medicine. Volume 187(2021)
• Publication Date: 2021-10
• Subjects: Interstitial lung disease -- Myositis autoantibody -- Connective tissue disease -- Autoimmune disease -- Immunoblot; Chest -- Diseases -- Periodicals; Chest -- Diseases -- Great Britain -- Periodicals; Respiratory organs -- Diseases -- Periodicals; Respiratory Tract Diseases -- Periodicals; Appareil respiratoire -- Maladies -- Périodiques; Thorax -- Maladies -- Périodiques; Appareil respiratoire -- Maladies -- Traitement -- Périodiques; Electronic journals; 616.2
• DOI: 10.1016/j.rmed.2021.106581
• Languages: English
• ISSNs: 0954-6111

Abstract

Abstract: Objectives: The detection of myositis autoantibodies (MA) in patients with interstitial lung disease (ILD) has major implications for diagnosis and management, especially amyopathic and forme frustes of idiopathic inflammatory myositis-associated ILD (IIM-ILD). Use of the MA line immunoblot assay (MA-LIA) in non-rheumatological cohorts remains unvalidated. We assessed the diagnostic performance of the MA-LIA and explored combined models with clinical variables to improve identification of patients with IIM-ILD. Methods: Consecutive patients referred to a specialist ILD clinic, with ILD-diagnosis confirmed at multidisciplinary meeting, and MA-LIA performed within six months of baseline were included. Pre-specified MA-LIA thresholds were evaluated for IIM-ILD diagnosis. Results: A total 247 ILD patients were included (IIM-ILD n = 12, non-IIM connective tissue disease-associated ILD [CTD-ILD] n = 52, idiopathic interstitial pneumonia [IIP] n = 115, other-ILD n = 68). Mean age was 64.8 years, with 45.3% female, mean FVC 75.5% and DLCO 59.2% predicted. MA were present in 13.8% overall and 83.3% of IIM-ILD patients. The most common MA in IIM-ILD and non-IIM ILD patients were anti-Jo-1 (prevalence 40%) and anti-PMScl (29.2%) autoantibodies respectively. The pre-specified low-positive threshold (>10 signal intensity) had the highest discriminative capacity for IIM-ILD (AUC 0.86). Combining MA-LIA with age, gender, clinical CTD-manifestations and an overlap non-specific interstitial pneumonia/organising pneumonia pattern on HRCT improved discrimination for IIM-ILD (AUC 0.96). Conclusion: The MA-LIA is useful to support a diagnosis of IIM-ILD as a complement to multi-disciplinary ILD assessment. Clinical interpretation is optimised by consideration of the strength of the MA-LIA result together with clinical and radiological features of IIM-ILD. Highlights: Use of the myositis autoantibody line-immunoassay (MA-LIA) in ILD cohorts is unvalidated. MA-LIA thresholds strongly influence test performance. Combining the MA-LIA with clinical variables enhances myositis-ILD identification. Validation of ILD-specific MA-LIA reference intervals is required. Positive MA in non-myositis patients require prospective, long-term characterisation.